Furthermore, fine-mapping efforts via deep-coverage sequencing confirmed that the PCSK9 variant rs11591147 lowers LDL-C and confers stroke protection, reinforcing its status as a prime therapeutic target [133]. This evidence concerns the gene PCSK9 and Stroke.